Skip to main content

Drug Interactions between ketoconazole and phenobarbital

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ketoconazole PHENobarbital

Applies to: ketoconazole and phenobarbital

GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the oral bioavailability and plasma concentrations of itraconazole and ketoconazole. In vitro studies have shown that CYP450 3A4 is the major enzyme involved in their metabolism, and pharmacokinetic studies as well as case reports have demonstrated decreases in itraconazole and ketoconazole systemic exposure (AUC) by at least 80% and sometimes even to undetectable levels when coadministered with potent CYP450 3A4 inducers such as rifampin or phenytoin, including reports of treatment failure.

MANAGEMENT: Concomitant use of itraconazole or ketoconazole with potent CYP450 3A4 inducers should generally be avoided. Some authorities recommend avoiding coadministration of potent CYP450 3A4 inducers from 2 weeks before and during treatment with these azole antifungal agents unless the benefits outweigh the risk of potentially reduced antifungal efficacy. If coadministration is required, clinical response and antifungal activity should be closely monitored and the itraconazole or ketoconazole dosage increased as necessary.

References (14)
  1. Abadie-Kemmerly S, Pankey GA, Dalvisio JR (1988) "Failure of ketoconazole treatment of blastomyces dermatidis due to interaction of isoniazid and rifampin." Ann Intern Med, 109, p. 844-5
  2. Brass C, Galgiani JN, Blaschke TF, et al. (1982) "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother, 21, p. 151-8
  3. Engelhard D, Stutman HR, Marks MI (1984) "Interaction of ketoconazole with rifampin and isoniazid." N Engl J Med, 311, p. 1681-3
  4. Tucker RM, Denning DW, Hanson LH, et al. (1992) "Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations." Clin Infect Dis, 14, p. 165-74
  5. Doble N, Shaw R, Rowland-Hill C, et al. (1988) "Pharmacokinetic study of the interaction between rifampicin and ketoconazole." J Antimicrob Chemother, 21, p. 633-5
  6. Meunier F (1986) "Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents." Eur J Clin Microbiol, 5, p. 103-9
  7. Schaferkorting M (1993) "Pharmacokinetic optimisation of oral antifungal therapy." Clin Pharmacokinet, 25, p. 329-41
  8. Drayton J, Dickinson G, Rinaldi MG (1994) "Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole." Clin Infect Dis, 18, p. 266
  9. Jaruratanasirikul S, Sriwiriyajan S (1998) "Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients." Eur J Clin Pharmacol, 54, p. 155-8
  10. Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Vandevelde V, Mannens G, Edwards DJ (1995) "Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin." Clin Pharmacol Ther, 58, p. 617-24
  11. (2024) "Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals
  12. (2024) "Product Information. Ketoconazole (ketoconazole)." Taro Pharmaceuticals U.S.A. Inc
  13. (2024) "Product Information. Sporanox (itraconazole)." Janssen-Cilag Pty Ltd
  14. Moon SM, Park HY, Jeong BH, Jeon K, lee sy, Koh WJ (2015) "Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection." Antimicrob Agents Chemother, 59, p. 663-5

Drug and food interactions

Major

PHENobarbital food

Applies to: phenobarbital

GENERALLY AVOID: Concurrent acute use of barbiturates and ethanol may result in additive CNS effects, including impaired coordination, sedation, and death. Tolerance of these agents may occur with chronic use. The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.

MANAGEMENT: The combination of ethanol and barbiturates should be avoided.

References (5)
  1. Gupta RC, Kofoed J (1966) "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J, 94, p. 863-5
  2. Misra PS, Lefevre A, Ishii H, Rubin E, Lieber CS (1971) "Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats." Am J Med, 51, p. 346-51
  3. Saario I, Linnoila M (1976) "Effect of subacute treatment with hypnotics, alone or in combination with alcohol, on psychomotor skills related to driving." Acta Pharmacol Toxicol (Copenh), 38, p. 382-92
  4. Stead AH, Moffat AC (1983) "Quantification of the interaction between barbiturates and alcohol and interpretation of fatal blood concentrations." Hum Toxicol, 2, p. 5-14
  5. Seixas FA (1979) "Drug/alcohol interactions: avert potential dangers." Geriatrics, 34, p. 89-102
Moderate

ketoconazole food

Applies to: ketoconazole

GENERALLY AVOID: Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury. Serious hepatotoxicity has been reported with levoketoconazole. Hepatotoxicity requiring liver transplantation has been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer. Some patients had no obvious risk factors for liver disease. In addition, use of alcohol or products containing alcohol during ketoconazole or levoketoconazole therapy may result in a disulfiram-like reaction in some patients. Symptoms of disulfiram-like reaction include flushing, rash, peripheral edema, nausea, and headache.

GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of ketoconazole or levoketoconazole. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Inhibition of hepatic CYP450 3A4 may also contribute. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.

When administered to healthy volunteers with a high-fat meal (875 calories; 62% fat), levoketoconazole systemic exposure (AUC) increased by 30% while peak plasma concentration (Cmax) did not change and the time to reach Cmax (Tmax) was delayed from 2 to 4 hours, compared to fasted conditions.

MANAGEMENT: Levoketoconazole may be administered with or without food. Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy. Patients should preferably avoid or limit consumption of grapefruit, grapefruit juice, or any supplement containing grapefruit extract during ketoconazole or levoketoconazole therapy. Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.

References (4)
  1. (2019) "Product Information. Ketoconazole (ketoconazole)." Mylan Pharmaceuticals Inc
  2. (2022) "Product Information. Recorlev (levoketoconazole)." Xeris Pharmaceuticals Inc
  3. Auchus R, Pivonello R, Fleseriu M, et al. (2022) Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440
  4. (2021) "Product Information. Ketoconazole (ketoconazole)." Burel Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.